MINNEAPOLIS & BOSTON--(BUSINESS WIRE)--Early findings from a Medtronic, Inc. (NYSE: MDT) sponsored study show heart failure patients with moderate ejection fractions, over 35 percent, may receive comparable benefits from cardiac resynchronization therapy (CRT) as compared to those with low ejection fractions of equal to or less than 35 percent. A retrospective analysis from the PROSPECT (Predictors of Response to CRT) study, the largest CRT post-market clinical study of its kind with primary endpoints measuring echocardiographic predictors of CRT response, suggests the potential for CRT to benefit more than 1 million heart failure patients worldwide who have an ejection fraction greater than 35 percent and are not currently indicated to receive CRT therapy.
